Berg D - Search Results

1

Iron as a therapeutic target for Parkinson's disease.

Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Moreau C, et al. Among authors: berg d. Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. Mov Disord. 2018. PMID: 29380903 Review. No abstract available.

2

Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound.

Becker G, Berg D. Becker G, et al. Among authors: berg d. Mov Disord. 2001 Jan;16(1):23-32. doi: 10.1002/1531-8257(200101)16:1<23::aid-mds1003>3.0.co;2-2. Mov Disord. 2001. PMID: 11215589 Review.

3

Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.

Berg D, Merz B, Reiners K, Naumann M, Becker G. Berg D, et al. Mov Disord. 2005 Mar;20(3):383-5. doi: 10.1002/mds.20311. Mov Disord. 2005. PMID: 15486999

4

Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients.

Berg D, Niwar M, Maass S, Zimprich A, Möller JC, Wuellner U, Schmitz-Hübsch T, Klein C, Tan EK, Schöls L, Marsh L, Dawson TM, Janetzky B, Müller T, Woitalla D, Kostic V, Pramstaller PP, Oertel WH, Bauer P, Krueger R, Gasser T, Riess O. Berg D, et al. Mov Disord. 2005 Sep;20(9):1191-4. doi: 10.1002/mds.20504. Mov Disord. 2005. PMID: 15895422

5

In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.

Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, Tampellini D, Riederer P, Gerlach M, Becker G. Zecca L, et al. Among authors: berg d. Mov Disord. 2005 Oct;20(10):1278-85. doi: 10.1002/mds.20550. Mov Disord. 2005. PMID: 15986424

6

Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease.

Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Schweitzer KJ, et al. Among authors: berg d. Mov Disord. 2006 Jan;21(1):94-8. doi: 10.1002/mds.20669. Mov Disord. 2006. PMID: 16114024

7

Iron metabolism in Parkinsonian syndromes.

Berg D, Hochstrasser H. Berg D, et al. Mov Disord. 2006 Sep;21(9):1299-310. doi: 10.1002/mds.21020. Mov Disord. 2006. PMID: 16817199 Review.

8

Predictive value of transcranial sonography in the diagnosis of Parkinson's disease.

Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D. Prestel J, et al. Among authors: berg d. Mov Disord. 2006 Oct;21(10):1763-5. doi: 10.1002/mds.21054. Mov Disord. 2006. PMID: 16874758 Clinical Trial.

9

Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome.

Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D. Godau J, et al. Among authors: berg d. Mov Disord. 2007 Jan 15;22(2):187-92. doi: 10.1002/mds.21230. Mov Disord. 2007. PMID: 17133515

10

Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity.

Schweitzer KJ, Behnke S, Liepelt I, Wolf B, Grosser C, Godau J, Gaenslen A, Bruessel T, Wendt A, Abel F, Müller A, Gasser T, Berg D. Schweitzer KJ, et al. Among authors: berg d. J Neural Transm (Vienna). 2007 Sep;114(9):1167-71. doi: 10.1007/s00702-007-0725-5. Epub 2007 Apr 20. J Neural Transm (Vienna). 2007. PMID: 17446999

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,361 results

Search Page